The autonomous vehicle leader Waymo has closed a massive $16 billion funding round, catapulting its valuation to $126 billion. The capital infusion is set to turbocharge its international expansion plans, even as it navigates operational challenges and intensifying competition from rivals like Tesla and Amazon's Zoox.
Facing the looming patent expiration of key drugs Revlimid and Eliquis, Bristol-Myers Squibb is making a strategic pivot, acquiring Orbital Therapeutics for $1.5 billion to pioneer in vivo RNA therapies. This high-stakes move aims to redefine the company's growth in oncology and autoimmune diseases.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
Amid a challenging retail landscape, Target Corporation (TGT) is drawing attention from value investors who argue its depressed stock price and reliable dividend profile present a compelling opportunity for steady returns.
Exclusive BBC analysis reveals nearly half of accredited zoos and aquariums in the UK and Ireland have sounded financial alarms since 2022, forcing tough choices between conservation missions and economic reality.
In an exclusive interview, GeneDx CEO Katherine Stueland details how rapid genomic testing is transforming pediatric care, slashing diagnosis times from years to days and building a data-driven bridge to future therapies.
Woodward (WWD) kicked off fiscal 2026 with robust earnings, driven by a surge in aerospace services and industrial sales. The company raised its full-year outlook but cautioned on supply chain pressures and announced a strategic wind-down of its volatile China On-Highway business.
Alphabet's autonomous vehicle unit Waymo is reportedly in talks to raise approximately $16 billion in a new financing round, which would value the company close to $110 billion. The move comes as the robotaxi pioneer faces heightened regulatory and public scrutiny following recent incidents involving its vehicles.
As housing affordability hits historic lows, financial author JL Collins challenges a core tenet of the American Dream, arguing that homeownership can be a trap for capital and mobility, especially for those seeking early financial independence.
Palantir Technologies' stock gained momentum Monday following an upgrade by William Blair, a move vindicated after hours by a strong Q4 earnings report that exceeded forecasts and set robust guidance for 2026.
Shares of Huntington Bancshares (HBAN) have climbed over 17% in the past 90 days, closing recently at $17.88. This rally has investors scrutinizing whether the regional bank's stock still holds value after its strong run, with some models suggesting a significant upside to fair value.
A recent adjustment to Ceres Power Holdings' price target by analysts signals a broader reassessment of the clean energy firm's market narrative and future trajectory, moving beyond a single figure to underlying story shifts.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
A high-stakes White House meeting between crypto executives and traditional bankers ended without a breakthrough on the contentious issue of stablecoin yields, casting doubt on the timeline for comprehensive market structure legislation. Both sides agreed to continue negotiations under pressure from the administration to reach a compromise this month.
Natural gas futures tumbled over 25% on Monday, hitting a three-week low, as a swift recovery in U.S. production and a warmer weather forecast alleviated supply concerns sparked by last week's Arctic blast.
As Palantir Technologies reports a massive surge in U.S. government revenue, CEO Alex Karp publicly defends the company's controversial surveillance platforms, insisting they contain safeguards against overreach. The defense comes amidst growing public and political scrutiny over its contracts with immigration enforcement agencies.
Shares of the data analytics firm jumped more than 5% following a strong quarterly report that exceeded expectations and featured ambitious growth projections for the coming year.
The autonomous vehicle giant, backed by a consortium of major investors, plans to deploy its driverless fleet in over a dozen new international cities following a funding round that values the company at $126 billion.
Palantir Technologies' stock surged after hours as its Q4 earnings and bullish 2026 guidance surpassed analyst forecasts, signaling a powerful acceleration in its AI software business and vindicating CEO Alex Karp's long-term strategy.
